Azole Drug Resistance as a Cause of Clinical Relapse in AIDS Patients with Cryptococcal Meningitis

Spitzer ED Spitzer SG Freundlich LF Casadevall A. Persistence of the initial infection in recurrent cryptococcal meningitis. Lancet 1992;341:595–96.

Casadevall A Spitzer E Webb D Rinaldi M. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother 1993;37:1383–6.

Velez JD Allendoefer R Luther M Rinaldi MG Graybill JR. Correlation of in vitro susceptibility with in vivo response in a murine model of cryptococcal meningitis. J I D 1993;168:508–10.

Foulds G Brennan DR Wajszczuk C Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 1988;28:363–6.

Johnson EM Richardson MD Warnock DW. In-vitro resistance to imidazole antifungals in Candida albicans . J Antimicrob Chemother 1984;13:547–58.

Warnock DW. Methods with antifungal drugs. In: Evans EGV Richardson MD , eds. Medical mycology; a practical approach. London: Oxford University Press, 1989; 235–59.

Como JA Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263–72.

Coker RJ Viviani M Gazzard BG Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993;7:829–35.

Berry AJ Rinaldi MG Graybill JR. Use of high dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother 1992;32:690–2.

Viviani MA Tortorano AM Langer M Experience with itraconazole in cryptococcosis and aspergillosis. J Infect 1989;18:151–65.

British Society for Antimicrobial Chemotherapy Working Party. Antifungal chemotherapy in patients with acquired immunodeficiency syndrome. Lancet 1992;340:648–51.

Nightingale SD Cal SX Peterson DM Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992;6:191–4.